This article is intended for primary care clinicians, obstetrician-gynecologists, nurses, public health officials, and other members of the healthcare team involved in the care of pregnant women and their infants.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Enduring Material activity, Medscape Education Clinical Briefs, has been reviewed and is acceptable for up to 65.00 Prescribed credit(s) by the American Academy of Family Physicians. Term of approval begins 09/01/2015. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
AAFP Accreditation Questions
Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / CE Released: 11/18/2015
Valid for credit through: 11/18/2016, 11:59 PM EST
processing....
Prenatal alcohol exposure, which can injure the developing infant, is the leading preventable cause of birth defects and intellectual and neurodevelopmental disabilities. Fetal alcohol syndrome was first described in 1973 as a specific cluster of birth defects caused by prenatal alcohol exposure, but later studies proved that such exposure leads to a wide variety of adverse developmental outcomes (fetal alcohol spectrum disorder).
Specific diagnostic criteria exist for fetal alcohol syndrome, and professional organizations are developing definitive diagnostic criteria for other fetal alcohol spectrum disorders. The American Academy of Pediatrics (AAP) issued a new clinical report on fetal alcohol spectrum disorders regarding prevention initiatives and recommended treatment approaches.
A new clinical report on fetal alcohol spectrum disorders from the AAP reiterates that no amount of alcohol consumption is safe during any trimester of pregnancy.
Prenatal alcohol exposure is the top preventable cause of birth defects and intellectual and neurodevelopmental disabilities in children, according to Janet F. Williams, MD, from the University of Texas Health Science Center at the San Antonio School of Medicine and the AAP's Committee on Substance Abuse. The report was published online October 19 in Pediatrics.[1]
"Earlier termination of alcohol use in pregnancy is associated with fewer alcohol-related complications for the mother and her baby," the authors write. "Specifically, first trimester drinking (vs no drinking) produces 12 times the odds of giving birth to a child with FASD [fetal alcohol spectrum disorder], first and second trimester drinking increases FASD odds 61 times, and drinking in all trimesters increases the FASD odds 65 times."
Despite these risks, a recent study from the US Centers for Disease Control and Prevention found that one in 10 women drink alcohol during pregnancy.[2]
Evolving Terminology
The new report is not the first the AAP has published on the subject of alcohol and pregnancy, but the terminology used to describe fetal alcohol spectrum disorders is evolving as researchers learn more about the wide range of effects that result from prenatal alcohol exposure.
"Fetal alcohol spectrum disorder is an overarching phrase that encompasses a range of possible diagnoses, including fetal alcohol syndrome (FAS), partial fetal alcohol syndrome, alcohol-related birth defects (ARBD), alcohol-related neurodevelopmental disorder (ARND), and neurobehavioral disorder associated with prenatal alcohol exposure (ND-PAE)," the authors explain.
"[R]esearch evidence suggests that ARBD may be declining in use while ARND/ND-PAE terminology remains incompletely defined," they add. "ND-PAE may become the accepted diagnostic term for moderate PAE findings, and 'static encephalopathy' associated with PAE is a suggested diagnostic term for severe PAE effects."
Fetal alcohol syndrome is a clinical diagnosis that is made on the basis of a specific combination of prenatal and/or postnatal growth deficiency, as well as the 3 "cardinal facial features" (reduced palpebral fissure length, smooth philtrum, and thin upper vermillion lip border), and any of the known structural, neurologic, and/or functional central nervous system deficits.
What to Look For
Neurocognitive and behavioral deficits from prenatal alcohol exposure last a lifetime, but early recognition, diagnosis, and therapy for any of the fetal alcohol spectrum disorders can help.
Unfortunately, a lack of uniformly accepted diagnostic criteria for fetal alcohol-related disorders has critically limited efforts that could lessen the effect of fetal alcohol spectrum disorders, Dr Williams explained in an AAP news release. "Even though fetal alcohol spectrum disorders are the most commonly identifiable causes of developmental delays and intellectual disabilities, they remain significantly under-recognized."
The primary role of a pediatrician and the medical home with respect to fetal alcohol spectrum disorder is to learn as much as possible about the disorder to be able to counsel patients on prevention, to know when and how to screen patients for the disorder, and to manage and refer patients for specialized services.
"Medical home care relevant to FASD patients includes documenting a PAE and other substance exposure history and other historical details as well as physical examination findings, diagnosing FAS in patients when possible, and/or referring for comprehensive FASD assessment and diagnostic evaluation for intervention," the authors write.
Primary care providers should suspect fetal alcohol spectrum disorder in children with "suggestive physical stigmata" and/or those who are being evaluated for poor growth, developmental delays, or behavioral issues. Children who have been adopted, especially those who come from poverty and those with child protective services involvement, may be more likely to have experienced prenatal alcohol exposure and need careful screening.
Children with any history of involvement with child protective services resulting from parental substance use, child neglect, abuse, or abandonment also have a high risk for fetal alcohol spectrum disorder and require screening, as do children with any out-of-home or foster care placement.
The AAP offers a toolkit on fetal alcohol spectrum disorder that includes information about common diagnostic approaches, common features of children with the disorder, diagnostic tools, an algorithm for evaluation, a provider checklist, and guidelines for referral and diagnosis.[3]
A list of frequently asked questions on fetal alcohol spectrum disorders for parents is also available online.[4]
The authors have disclosed no relevant financial relationships.